Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
GREP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GREP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GREP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GSK3A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GSK3A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GSK3A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
HIPK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
HIPK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of HIPK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GASK1A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GASK1A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GASK1A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FLVCR2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FLVCR2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of FLVCR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GLYCTK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GLYCTK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GLYCTK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FLVCR1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FLVCR1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of FLVCR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GKAP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GKAP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GKAP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FLRT2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FLRT2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of FLRT2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FAM20B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FAM20B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of FAM20B sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FAM20C Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FAM20C Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of FAM20C sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FLRT1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FLRT1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of FLRT1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →